Globus Medical Shares Race Higher After Better-Than-Expected Q1 Results

Zinger Key Points
  • Globus Medical reports quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32%.
  • Quarterly sales come in at $606.67 million which beat the analyst consensus estimate by 3.33% and is a 119.26% increase in sales YoY.

Globus Medical, Inc. GMED shares are trading higher Wednesday after the company posted better-than-expected first-quarter financial results and raised its fiscal year 2024 guidance. 

The Details:

Globus Medical reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32% and represents a 35.85% increase over earnings from the same period last year. 

Quarterly sales came in at $606.67 million which beat the analyst consensus estimate by 3.33% and is a 119.26% increase in sales year-over-year. 

“Since the NuVasive merger closed in September of last year, we worked aggressively to execute our integration strategy and are making significant progress towards rapidly reaching steady state. I am pleased with the first quarter results delivered by strong teamwork and partnership throughout our organization. Surgeons and hospitals are responding favorably to our best-in-class product offering of clinically advanced devices and enabling technologies and worldwide sales reflect the long-term potential of our company,” said Dan Scavilla, CEO of Globus Medical. 

Outlook:

The company updated its guidance for full year 2024 revenue to be in the range of $2.46 billion to $2.485 billion and earnings per share in the range of $2.75 to $2.85. The updated guidance is an increase over the prior full year 2024 revenue guidance of $2.45 billion to $2.475 billion and earnings per share guidance of $2.68 to $2.70.

Analysts React: 

Multiple analysts raised their price targets on the stock after the print:

  • BTIG analyst Ryan Zimmerman maintained a Buy rating and raised the price target from $60 to $63.
  • Piper Sandler maintained Globus Medical with a Neutral and raised its price target from $55 to $60.
  • Stifel analyst Mathew Blackman maintained a Buy rating and raised the price target from $64 to $70.

Related News: Reddit Shares Soar On First Post-IPO Q1 Results, Strong Q2 Guidance

GMED Price Action: According to Benzinga Pro, Globus Medical shares are up 23.6% at $63.50 at the time of publication Wednesday.

Image: PublicDomainPictures from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!